Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis.
Manuela ColucciRaffaella LabbadiaMarina VivarelliFrancesca Diomedi CamasseiFrancesco EmmaLuca Dello StrologoPublished in: Pediatric nephrology (Berlin, Germany) (2019)
Ofatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.